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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by
a selective loss of motor neurons together with a progressive muscle weakness. Albeit the
pathophysiological mechanisms of the disease remain unknown, growing evidence sug-
gests that skeletal muscle can be a target of ALS toxicity. In particular, the two main intracel-
lular degradation mechanisms, autophagy and the ubiquitin-proteasome degradative
system (UPS) have been poorly studied in this tissue. In this study we investigated the acti-
vation of autophagy and the UPS as well as apoptosis in the skeletal muscle from
SOD1G93A mice along disease progression. Our results showed a significant upregulation
of proteasome activity at early symptomatic stage, while the autophagy activation was
found at presymptomatic and terminal stages. The mRNA upregulated levels of LC3, p62,
Beclin1, Atg5 and E2f1 were only observed at symptomatic and terminal stages, which rein-
forced the time-point activation of autophagy. Furthermore, no apoptosis activation was
observed along disease progression. The combined data provided clear evidence for the
first time that there is a time-point dependent activation of autophagy and UPS in the skele-
tal muscle from SOD1G93A mice.
Introduction
Autophagy and the ubiquitin-proteasome degradative system (UPS) are considered two main
critical mechanisms that contribute to basal elimination of misfolded proteins and hence, they
maintain the balancing protein homeostasis inside cells. Albeit autophagy was initially
described as a central mechanism for cell survival under starvation conditions, a growing num-
ber of studies indicate that autophagy can play a relevant role in eliminating protein aggregates,
especially in neurodegenerative diseases, mainly because its activation can efficiently degrade
misfolded mutant proteins[1].
ALS is one of the most known neurodegenerative diseases characterized by a selective loss
of motor neurons together with a progressive muscle weakness. The first studies that connected
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an impairment in autophagy to the progression of ALS showed a significant upregulation of
the activated microtubule-associated protein 1 light chain (LC3) protein levels at the end symp-
tomatic stage in the spinal cord from SOD1G93A mice, one of the best characterized animal
models of the disease[2, 3]. At this step, autophagy, an intracellular process that leads to the
elimination of cytoplasmic components inside lysosomes, was proposed as the main process
that degraded mutant SOD1 in vitro and in vivo in the spinal cord from SOD1G93A mice[4].
Remarkably, a wide range of studies have characterized till now the possible cause of autophagy
impairment in different experimental models for ALS[5–13]. In addition, mutant SOD1 aggre-
gates not only induce impairment in proteasome activity but also alterations in SOD1 intracel-
lular distribution[14]. In particular, there is clear evidence that endoplasmic reticulum (ER)
stress correlates directly to motor neuron loss and ALS progression and interestingly, the adap-
tative responses to ER stress through protein folding pathways, such as unfolded protein
response (UPR) are also closely related to autophagy in mutant SOD1 transgenic mice [7, 8].
The UPR is the main protective mechanism during ER stress and it promotes either protein
folding or degradation of misfolded proteins. Precisely, the UPS is an important mechanism
for the degradation of misfolded proteins exporting from ER and its failure can lead to signifi-
cant ER stress[7, 15–17].
In this complex scenario and taking into consideration that the main cause of ALS disease
remains unknown, the need for studying autophagy not as a single process but just in connec-
tion with other related processes such as the UPS, becomes relevant to a better understanding
of the molecular basis of ALS. It is worth noting that both autophagy and proteasome were pro-
posed as essential mechanisms for the reduction of mutant SOD1-mediated neurotoxicity in
familial ALS (fALS), the genetic form of the disease [5, 18]. However, little information has
been reported regarding autophagy and proteasome activity in one of the most affected tissues
of the disease, the skeletal muscle, which is a more accessible tissue than spinal cord or brain in
potential therapeutic strategies. Actually, muscle weakness has been described as one of the
major causes of disability in ALS and for this reason the better understanding of the way ALS
can affect skeletal muscle function becomes essential.
As a matter of fact, previous studies have characterized the skeletal muscle as a primary tar-
get of mutant SOD1 toxicity and the need for modulation of autophagy as a potential therapeu-
tic intervention to counteract muscle atrophy has been also proposed [9, 19, 20]. Recent data
reported that mutant SOD1 clearance was higher in muscles than in motorneurons. Taking
into consideration that proteasome impairment has been shown to trigger autophagy, in this
study, we investigated the role of autophagy in skeletal muscle tissue from SOD1G93A mice
along disease progression and in connection with the UPS. Our results revealed a novel finding
about the time-point dependent activation of autophagy and the UPS in this tissue.
Materials and Methods
Animals and skeletal muscle samples
Transgenic mice expressing the G93A mutant human SOD1 were originally obtained from
The Jackson Laboratory (B6SJLTg(SOD1G93A)1Gur/J). Hemizygotic transgenic mice were
obtained by mating transgenic males with F1 females (B6SJL). The offspring were identified by
PCR amplification of DNA extracted from tail tissue with specific primers for human SOD1.
Wild type (WT) littermates were used as controls for all experiments. Hemizygous SOD1G93A
mice at the following days of life were used: 40 (presymptomatic, P40), 60 (early symptomatic,
P60), 90 (symptomatic, P90) and 120 (terminal stage, P120). The animals were housed in the
Unidad Mixta de Investigación of the University of Zaragoza under a 12h light/dark cycle.
Food and water were available ad libitum. The care and use of animals were performed
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accordingly with the Spanish Policy for Animal Protection RD53/2013, which meets the Euro-
pean Union Directive 2010/63/UE on the protection of animals used for experimental and
other scientific purposes. All of the experimental procedures were approved by the in-house
Ethic Committees for Animal Experiments of the University of Zaragoza.
All experimental groups were balanced to avoid sex bias [21]. The mice were sacrificed by
CO2 anesthesia and skeletal muscles from both hindlimbs were dissected. Skeletal muscle tis-
sues, for gene and protein expression studies, were snap-frozen and preserved at -80°C until to
be pulverized in liquid nitrogen with a cell crusher. The powdered tissue was divided equally
for RNA and protein extraction. For TUNEL and immunofluorescence assays, skeletal muscle
tissue was removed, fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for
24 hours and cryopreserved in 30% sucrose for 48 hours. Sample tissues were embedded in
OCT (Tissue-Tek, Sakura Finetek) and frozen in liquid nitrogen-cooled 2-methylbutane. The
tissue blocks were stored at -80°C.
mRNA expression
For RNA extraction, powdered muscle tissue was homogenized with Trizol Reagent (Invitro-
gen) (n = 10 animals per time point and genotype, 5 males and 5 females) using a PRO200
homogenizer (PRO Scientific Inc.). RNA extracted was treated to eliminate genomic DNA
using the Turbo DNA-free kit (Ambion). Reverse transcription was carried out according to
the SuperScript First-Strand Synthesis System kit (Invitrogen). Gene expression variations in
all of the samples were assayed by real-time PCR in an ABI Prism 7000 Sequence Detection
System (Applied Biosystems). Primer and probe mixtures for each gene (LC3
(Mm00458724_m1), p62 (Mm00448091_m1), Beclin1 (Mm00517174_m1), Atg5
(Mm00504340_m1) and E2f1 (Mm00432939_m1)) were supplied by Applied Biosystems. Two
endogenous genes (GAPDH and β-actin) were used for normalization of the data [22, 23]. All
reactions were performed in triplicate and the reaction efficiencies of the primer/probe sets
were close to 100%.
Immunoblot analysis
The powdered skeletal muscle tissue (n = 12 animals per time point and genotype, 6 males and
6 females) was resuspended in RIPA lysis buffer with protease inhibitors (Complete, Roche) and
the homogenate were centrifuged at 10.000 g for 10 min at 4°C. The supernatants were collected
and the protein concentration was quantified by BCAmethod (Sigma-Aldrich). Forty micro-
grams of protein was resolved on a 15% SDS-page gel and the proteins were transferred to
PVDF membranes (Amersham Biosciences). The membranes were blocked in Tris-buffered
saline supplemented with 0.1% Tween 20 and 5% (w/v) powered skim milk overnight at 4°C
and then incubated with primary antibodies for one hour at room temperature (RT) against
LC3 (1:1000; PD014, MBL), p62/SQSTM1 (1:1000; BML-PW9860, Enzo Life Sciences), Beclin1
(1:500; sc-11427, Santa Cruz), Caspase-3 (1:500; 9662, Cell Signalling), Caspase-9 (1:500; 9508,
Cell Signalling), Bax (1:1000; sc-526, Santa Cruz), Bcl2 (1:1000; sc-492, Santa Cruz), PARP-1
(1:500; sc-7150, Santa Cruz) and GAPDH (1:1000; sc-25778, Santa Cruz). After incubation with
HRP-conjugated secondary antibodies, bands were visualized by ECL reagents (GE Healthcare
Life Science). Inmunoblots were scanned and densitometry was measured with AlphaEase FC
software (Bonsai). Results were normalized to the corresponding GAPDH signal.
Inmunofluorescence
Transverse sections of skeletal muscle (10 μm) were cut with using a cryostat (CM1510S Leica
Microsystems). Tissue sections were re-fixed on ice with formalin solution 10% (HT5014,
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Sigma) for 10 min, permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate in PBS for
10 min at RT, and blocked with 10% goat serum and 1% BSA in PBS for 30 min at RT. After
washes, sections were incubated with primary antibodies over night at 4°C against Beclin1
(1:50; sc-11427, Santa Cruz) and LC3 (1:200; PD014, MBL), and subsequently incubated with
Alexa Fluor 546 goat anti-rabbit IgG (Invitrogen) for 1 h at RT. Nuclear staining (in blue) was
performed using a mounting medium with DAPI (Vectashield, H-1200, Vector Laboratories)
and visualized on an Olympus IX81 fluorescence microscope.
Proteasome activity
Skeletal muscle tissue was homogenized in cold buffer (20 mM TrisHCl pH 7.5, 2 mM EDTA)
and centrifuged at 15000 g for 10 min at 4°C (n = 6 animals per time point and genotype, 3
males and 3 females). Protein concentration in supernatants was determined using the BCA
protein assay. All samples were assayed in triplicate using 10 μg of freshly protein extracts. Pro-
teasome activity was measured using the CHEMICON Proteasome Activity Assay Kit
(APT280, Millipore) as described by the manufacturer. The extracts were incubated (2 h at
37°C) with a labelled substrate, LLVY-7-amino-4-methylcoumarin, and the cleavage activity
was monitored by detection of the free fluorophore 7-amino-4-methylcoumarin using a fluo-
rescence plate reader (Infinite F200 PRO, TECAN) at 360/460 nm.
Chloroquine treatment
Skeletal muscle tissue (n = 6 SOD1G93A mice at P120, 3 males and 3 females) were dissected
and the tissue was then chopped into small pieces. The explants were rinsed in phosphate-buff-
ered saline (PBS) prior to being cultured in DMEM containing 10% (v/v) fetal bovine serum
and 100 μM chloroquine (C6628,Sigma-Aldrich) for 6 hours at 37°C and 5% CO2. After cul-
ture, the explants were washed twice with PBS, snap-frozen and preserved at -80°C. For protein
extraction, explants were processed as described above and LC3-II expression was assessed.
Apoptotic detection
Detection of apoptotic nuclei was assessed by TUNEL assay (Terminal deoxynucleotidyl trans-
ferase fluorescein-dUTP nick end-labelling) using the In situ Cell Death Detection kit (Roche)
in transverse sections of 10 μm. The positive controls were carried out on serial sections after
prior incubation with DNAse I, while negative control used label solution instead of TUNEL
reaction mixture. Slides were mounted with Vectashield with DAPI (Vectashield, H-1200, Vec-
tor Laboratories). The percentage of apoptotic cells was determined by counting TUNEL-posi-
tive cells on an Olympus IX81 fluorescence microscope.
Statistical analysis
Results obtained from SOD1G93A and control groups were compared using Student’s t-test or
ANOVA followed by Bonferroni post-hoc test. All of the values were expressed as means and
error bars represent standard error of the mean (SEM). The statistical significance threshold
was set at p<0.05. The software used for the statistical analysis was SPSS 19.0 (IBM).
Results
Activation of autophagy at presymptomatic and the late stages of the
disease
To characterize the autophagy machinery in SOD1G93A mice along disease progression, the
mRNA levels of Lc3, p62, Beclin1, Atg5 and E2f1 genes were first quantified by real-time PCR in
Autophagy and UPS in SOD1G93AMice
PLOS ONE | DOI:10.1371/journal.pone.0134830 August 5, 2015 4 / 15
the skeletal muscle tissue of WT and SOD1G93Amice at P40, P60, P90 and P120. At asymp-
tomatic stage (P40) no significant changes were found. At early symptomatic stage (P60),
mRNA levels of Beclin1 and Atg5 were significantly downregulated in SOD1G93Amice, while
upregulated levels were found in the case of E2f1. However, at symptomatic and terminal stages
of the disease (P90 and P120) all the analyzed transcripts were significantly upregulated (Fig 1).
Moreover, we analyzed the protein expression of three widely used autophagy markers,
Beclin1, LC3 and p62 along disease progression. The expression of Beclin1 was significant
increased in all stages except at P90 when no differences were detected between WT and
SOD1G93A. In case of LC3-II and p62, the expression levels of both proteins remained almost
unchanged until P90. A statistically significant downregulation of p62 levels were observed at
P40, while a significant impairment was found in LC3-I levels at the first stages of the disease.
However, at P120, a significant upregulation was found in Beclin1, LC3-I, LC3-II and p62 (Fig
2A). Furthermore, the ratio LC3-II/LC3-I showed that the autophagy flux was significant
increased at P40 and P120 while decreased at P60 (Fig 2B).
The upregulation of Beclin1, LC3-II and p62 levels at P120 could point out to an activation
of autophagy process or just its blockage. Therefore, in order to shed light on this question, we
next assessed the autophagic flux. At this point, skeletal muscle samples from SOD1G93A mice
were treated with chloroquine, an agent that impairs lysosomal acidification. The results showed
an accumulation of LC3-II, so this would indicate that the upregulated levels of Beclin1, LC3-II
and p62 were a consequence of an enhancement of the autophagic flux (Fig 2C) [24].
Moreover, we also characterized the expression partner of Beclin1 and LC3 in the skeletal
muscle tissue using immunofluorescence staining. The expression of both proteins was consis-
tent with the pattern described above (Fig 3).
Activation of proteasomal activity at early symptomatic stages
Proteasome activation is the primary pathway by which proteins are cleared from cells [25].
Given the late activation of autophagy in SOD1G93A mice, we further investigated whether
autophagy impairment influenced proteasomal activation at early stages. For these purpose,
we measured the activity of the 20S proteolytic component of the 26S proteasome. In
SOD1G93A mice, the proteasomal activity was significantly reduced at P40, P90 and P120,
while at P60 the proteasome was significantly activated (Fig 4). These results suggested an
impairment in proteasome function in the skeletal muscle of SOD1G93A mice in the main
stages of the disease and the activation peak at P60 could imply a time-dependent way of
action in the proteasomal degradation.
Absence of apoptosis activation in skeletal muscle tissue
To further study in depth the role of the time-dependent activation of autophagy and protea-
some in the disease, we determined the role of apoptosis in the progression of the disease.
Western blot analysis for the total and the cleaved form of caspase-3, caspase-9, Bax, Bcl-2 and
the poly ADP ribose polymerase (PARP) profile expression pattern was performed. The cas-
pase-3 and caspase-9 has been described as the final effector of the apoptotic cell death mecha-
nism meanwhile the proteolytic cleavage (activation) of PARP-1 has been considered as a
hallmark biochemical feature of apoptosis,. Interestingly, the proteins caspase-3 and caspase-9
in its active form were no detected in WT or SOD1G93A mice as well as PARP-1 (S1 Fig).
However, the highest procaspase-3 and procaspase-9 expression levels were found at P90
(p>0.001) and P120 (p>0.001) respectively. Moreover, the activity of Bcl-2, an anti-apoptotic
protein, decreased significantly at P40 and increased significantly at the terminal stage, P120
(p<0.05) (Fig 5A). These data suggested that apoptosis was not exerting a decisive role in the
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Fig 1. mRNA expression levels of autophagy markers.Relative expression values of Lc3, p62, Beclin1, Atg5 and E2f1 in SOD1G93Amice (grey bars)
and wild type mice (WT, black bars) at each studied stage. Each data point represented the mean ± SEM. n = 10 animals per time-point and genotype. *p
<0.05, **p <0.01 and ***p <0.001 versus age-matchedWT.
doi:10.1371/journal.pone.0134830.g001
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skeletal muscle tissue from SOD1G93A mice. In addition, to verify the western blot results, the
apoptosis was visualized by TUNEL assay. As shown in Fig 5B, the percentage of TUNEL posi-
tive cells was very low at any stage of the disease (less than 1%) in all the tested samples from
WT or SOD1G93A mice. Moreover, not significant differences were detected between WT and
SOD1G93A mice, supporting the fact that the apoptotic cell death was not happening in the
skeletal muscle from SOD1G93A mice along disease progression.
Fig 2. Autophagy protein expression. (A) Western blots for Beclin1, LC3-II, LC3-I and p62 protein levels in SOD1G93Amice (grey bars) and age-matched
wild type mice (WT, black bars) along disease progression. The cropped blots portrayed are representative of independent experiments. All gels were run
under exact same experimental conditions for best comparison. Data showed mean ± SEM, n = 12 animals per time-point and genotype. *p <0.05 and ***p
<0.001 versus age-matchedWT. (B) Results of LC3-II were normalised to the corresponding LC3-I signal to generate ratio LC3-II/LC3-I in SOD1G93Amice
(light grey bars) and age-matched wild type mice (WT, black bars). Data showed mean ± SEM. *p <0.1, **p <0.01 and ***p <0.001. (C) Relative expression
levels of LC3-II from SOD1G93Amice at P120, before (light grey bars) and after chloroquine treatment (dark grey bars). Data showed mean ± SEM. n = 6
animals. *p <0.05.
doi:10.1371/journal.pone.0134830.g002
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Fig 3. Immunofluorescence of Beclin1 and LC3 staining. Beclin1 (A) and LC3 (B) staining was performed in skeletal muscle tissue from wild type (WT)
and SOD1G93Amice. DAPI staining was also performed (blue). A merged image of the double staining is presented. A representative image presents of 3
independent animals for genotype and disease stages. Scale bars: 100 μm.
doi:10.1371/journal.pone.0134830.g003
Autophagy and UPS in SOD1G93AMice
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Discussion
Skeletal muscle is one of the target tissues dramatically affected by the degenerative progression
of ALS. Actually, this tissue plays an important role in the neurophysiologic diagnosis of the
disease and therefore it may be considered a primary target of ALS toxicity[26–28].
The role of autophagy in SOD1G93A mice was just described as one of the major intracellu-
lar mechanism involved in muscle atrophy[19]. The oxidative stress induced in this animal
model is sufficient to activate autophagy. Interestingly, in MLC/SOD1G93A mice, in which the
overexpression of mutated SOD1 is restricted to skeletal muscle, the siRNA inactivation of
LC3, an essential marker for autophagosome formation, led to the rescue of the muscle pheno-
type[19]. Furthermore, not only autophagy but also the ubiquitin-proteasome degradative sys-
tem (UPS) is more markedly induced in muscle cells than in motor neurons[29, 30].
In this study, we further investigated the activity of autophagy and the UPS as well as the
apoptosis that could explain the induction of muscle atrophy in SOD1G93A mice.
In relation with autophagy, at presymptomatic stage (P40), the mRNA levels of LC3, p62,
Beclin1, Atg5 and E2f1 in SOD1G93A mice were similar to WT mice. However, the expression
of Beclin1 protein, a well-known key regulator of autophagy, and the ratio LC3-II/LC3-I was
increased, so these results could be related with an autophagy activation. It has been described
that the mutant SOD1G93A protein may promote the early increase in autophagic activity.
Indeed, this activation has been observed both in skeletal muscle cell line C2C12 [9] and in the
skeletal muscle fibers from SOD1G93A mice [31].
At the beginning of the disease (P60), Beclin1 and Atg5 levels significantly decreased mean-
while E2f1 levels increased in SOD1G93A with respect to WT mice. Beclin1, Atg5 and E2f1 are
components of the autophagy initiation complex; therefore, the Beclin1 and Atg5 deregulation
suggested an autophagy inhibition in this time point in spite of the upregulated E2f1 levels. In
particular, Beclin1 plays a relevant role in the regulation and induction of a correct autophagy
flux in muscle during fasting and precisely, a muscle specific inactivation of Atg5 gene deter-
mines a severe muscle wasting in mice[32]. Therefore, the downregulation of these two mark-
ers pointed out to an insufficient autophagy, being detrimental for muscle homeostasis.
Moreover, transcriptional activity of E2f1 plays an important role in the induction of autop-
hagy. Furthermore, it has been described that E2f1 and its truncated form E2f1tr, lacking the
transactivation domain, can upregulate the expression levels of autophagic genes such as LC3
and Atg5[33, 34]. In spite of the well described role of E2f1 in the modulation of both apoptosis
Fig 4. Proteasome activity. Proteasome activity was measured in skeletal muscle homogenates from
SOD1G93Amice (grey bars) and age-matched wild type mice (WT, black bars) at each stage of the disease.
Data showed mean ± SEM. n = 6 animals per time-point and genotype. *p <0.05 and ***p <0.001.
doi:10.1371/journal.pone.0134830.g004
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and autophagy, mainly in melanoma and embryonic cell lines, the upregulated levels of E2f1
found in the skeletal muscle from SOD1G93A mice at P60 could not be sufficient enough to
prompt the activation of LC3 and, above all, Beclin1 and Atg5. At protein level, the lower ratio
LC3-II/LC3-I and an absence of increased LC3-II level suggested a decreased autophagosome
formation and therefore a lack of autophagy activation in SOD1G93A mice. However, the
expression of Beclin1 was increased. Beclin1 has been described to play a central role in autop-
hagy and also in numerous biological processes including apoptosis [35]. In fact, it has been
described an abnormal association of Beclin1 with mutant SOD1 in ALS disease that may alter
the autophagy process [36].
Following with the autophagic response in skeletal muscle, at symptomatic stage P90, the
mRNA expression of autophagy makers were upregulated, but at protein level, contrary to
expectations, no differences were detected between WT and SOD1G93A mice. Thus, our data
Fig 5. Apoptosis activity. (A) Protein expression profile of apoptotic markers, Bax, Bcl-2 and procaspase-3, in SOD1G93Amice (grey bars) and age-
matched wild type mice (WT, black bars) along disease progression. Data showed mean ± SEM, n = 12 animals per time-point and genotype. *p <0.05 and
***p <0.001 versus age-matchedWT. (B) Detection of apoptotic nuclei by TUNEL assay at each stage of the disease. Data showed mean ± SEM, n = 8
animals per time-point and genotype.
doi:10.1371/journal.pone.0134830.g005
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suggested an impairment in the autophagy of SOD1G93A mice. We hypothesized that at P90
the skeletal muscle could prompt a regenerative response instead of an autophagy activation.
In fact, in the muscle from this animal model, the myogenic regulatory factors were mostly
increased at protein level especially while at P120 no protein increase was observed [37].
Finally, at terminal stage, the increased expression both gene and protein level could be
related with an autophagy activation. To determine if this upregulation was a consequence of a
blockage or an activation of autophagy, we blocked the activity using chloroquine in
SOD1G93A mice. Chloroquine inhibits autophagy by inhibiting the acidification of autopha-
gosome and maturation of autolysosome, resulting in the accumulation of autophagic vesicles
and the inhibition of autolysosomal protein degradation. The pharmacological inhibition of
autophagy by chloroquine has been previously tested in in vitromodels of ALS, but to date no
data has been registered in skeletal muscle cells[38]. After treating with chloroquine the
explants from skeletal muscles, significant LC3-II increased levels were observed, suggesting
that autophagy was still activated. As a consequence, the upregulation of LC3-II and p62 indi-
cated a significant activation of autophagy flux at this terminal stage. These data are consistent
with previous studies in the same tissue, in which mRNA and protein levels of LC3 and p62
were found significantly increased in SOD1G93A and in MLC/SOD1G93A mice at later stages
of the disease, suggesting that muscle cells were still able to upregulate these two essential
markers of autophagy [19, 30].
The next question that arouse to us was the study of the mechanisms that could be in clear
connection with autophagy to manage the degenerative progression of the disease in skeletal
muscle tissue. The relation between autophagy and the UPS seems to be close enough to finely
remove the intracellular accumulation of mutant SOD1 aggregates[15]. Actually, p62 partici-
pates in both mechanisms to eliminate ubiquitinated proteins from cells. At this step and tak-
ing into consideration the significant autophagy activation at P120, we wonder if the
proteasome activation could start earlier than autophagy in the skeletal muscle. Previous stud-
ies in this animal model showed that soluble mutant SOD1 in skeletal muscle did not have
direct effects on mitochondrial dysfunction, protein misfolding and muscle loss[30, 39]. How-
ever, the expression of mutant SOD1 in this tissue induced atrophy and mitochondrial abnor-
malities, favouring proteasome degradation under proteotoxic conditions, such as misfolded
mutant SOD1 overexpression[30, 40]. In accordance with these studies, our results showed an
impairment in proteasome activity along disease progression. In particular, a significant upre-
gulation of proteasome activity was only found at P60when autophagy process was clearly inac-
tivated. These results suggested that the proteasome degradation was only activated at early
symptomatic stage in skeletal muscle tissue.
On the other hand, many works suggest that there is an interplay between apoptosis and
autophagy [35, 41, 42]. In this interconnection, Beclin1 plays a critical role. Thus, Beclin1 is able
to bind PtdIns3KC3 and additional Atg proteins that organize autophagosome formation. In a
normal condition, Bcl2 binds to the complex PtdIns3K-Beclin1; but when Bcl2 is release, the com-
plex PtdIns3K-Beclin1 is activated and the autophagy is prompting by autophagosome formation.
Moreover, the protein levels of Beclin1 are controlled by caspase-dependent cleavage, one of the
most common signalling cascades involved in apoptosis, and the resulting fragments are unable
to induce autophagy [35]. To this end, the apoptosis was studied during ALS progression.
The activated caspases initiate cell death by cleaving several proteins such as PARP-1. Cleav-
age of PARP-1 by caspases is considered to be a hallmark of apoptosis [43]. However, in our
SOD1G93A mice the effectors caspase-3 and caspase-9 as well as PARP-1 cleavage were not
detected (Supporting information S1). These results suggested that apoptosis might not be trig-
gered along disease progression in the skeletal muscle from SOD1G93A mice. To verify these
results and taking into consideration previous studies in vitro in which autophagy protected
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muscle cells after chemical and physical stimuli[44], we performed a Tunel assay to study more
accurately the apoptosis activation. Interestingly and contrary to previous studies that revealed
caspase-mediated apoptosis at paralysis stage[45], no significant differences were detected
between WT and SOD1G93A mice, reinforcing the fact that apoptosis was not activated in any
studied stage of the disease. These results were in accordance with a previous study in a mouse
model that lacked the antioxidant enzyme Sod1 (Sod1 -/- mice). The chronic oxidative stress
induced in this animal model exacerbated muscle atrophy, leading to the activation of mito-
chondrial-mediated myonuclear apoptosis[46]. However, in the skeletal muscle from
SOD1G93A mice no apoptosis activation was found, pointing out to the fact that mutant
SOD1 was not directly influencing mitochondrial dysfunction as previously reported[30, 39].
Furthermore, in connection with this result it is interesting to note that rapamycin, an autop-
hagy enhancer, accelerated the motor neuron degeneration in SOD1G93A mice and it exacer-
bated the pathological progression mainly through apoptosis, suggesting that specific stimuli
could possibly trigger the tissue degeneration through apoptosis[47].
Conclusions
The data presented here uncover for the first time that there is a time-point dependent activation
of autophagy and UPS in the skeletal muscle from SOD1G93Amice. It has been described their
compensatory way of action, in other words, the autophagy activation is prompted when the
UPS impairment is present, and therefore autophagy blockage directly influences the UPS func-
tion [48]. Based on the fact that a failure of the UPS function is relevant in the neurodegenerative
progression in motor neuron diseases, our results are in line with this point, since the activation
of proteasome activity was only relevant at early symptomatic stage and this activation was pre-
ceded and followed by the autophagy activation at presymptomatic and terminal stages. Taking
into consideration that in skeletal muscle, in contrast to other tissues, the activation of autophagy
can persist for long periods of time, the transient activation of autophagy at early and late stages
in SOD1G93Amice could suggest a deregulation of this process along disease progression due to
the degeneration related to ALS. These findings provide new insights into the role of autophagy
in the progression of ALS, although further studies are required to completely unravel unknown
features of this protein degradation mechanism and its close relation to the UPS.
Supporting Information
S1 Fig. Positive control for Apoptosis. Apoptosis may be induced in experimental systems
through chemical agents such as doxorubicin. After confirming that mesenchymal stem cells
from SOD1G93A mice were growing by visual inspection, the DNA damaging agent (doxoru-
bicin 2 μM) was added. The cells were checking 24 hours later to determine if cells have begun
to apoptose. Finally, the cells were harvested; the protein was extracted and the western blot
was performed following the described protocol in Material and Methods. As shown in this fig-
ure, PARP-1, caspase-3 and caspase-9 proteins were only detected in positive control (C+). In
rest of samples, wild type as well as SOD1G93A mice (at P40, P60, P90 and P120), the cleaved
caspase-3, caspase-9 and PARP-1 were no detected.
(TIF)
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